<DOC>
	<DOC>NCT02746328</DOC>
	<brief_summary>This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.</brief_summary>
	<brief_title>Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass</brief_title>
	<detailed_description />
	<criteria>1. In screening for, and ultimately randomized into, protocol G200802 2. Give voluntary, written and signed, informed consent for this addon study 3. Age 18 to 70 years old 4. Physically capable of mounting and riding a stationary bicycle 5. Subject agrees to not significantly alter physical activity or current physical training during the study period 1. Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator 2. Subjects unwilling to or unable to comply with the protocol 3. Any other condition which per investigators' judgement may increase subject risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>